The short version for patients
Two FDA steps in 2026 moved several popular peptides closer to legitimate pharmacy supply, but neither finished the job. BPC-157, TB-500 and GHK-Cu are no longer on the FDA’s list of compounding substances that may pose significant safety risks, and an FDA advisory panel has recommended allowing BPC-157 and TB-500 in 503A compounding. The FDA has not issued a final rule.
That leaves patients in a gray zone. These peptides are closer to a regulated path than they were in 2025, yet whether a licensed pharmacy can supply them, and on what terms, is still unsettled. The rest of this article explains each step and what it does and does not change.
| Date | What happened | What it means now |
|---|---|---|
| April 2026 | BPC-157, TB-500 and GHK-Cu removed from FDA Category 2 after nominations were withdrawn | No longer flagged as a significant safety risk list item; not yet approved for compounding |
| July 23, 2026 | Advisory committee voted 8 to 6 to recommend BPC-157 and TB-500 for the 503A bulks list | A recommendation only; FDA staff had advised against it |
| Pending | FDA decision and rulemaking on the 503A bulks list | Determines whether pharmacies can compound them |
| By early 2027 | GHK-Cu scheduled for the same type of review | Status unsettled until then |
April 2026: off the safety-concern list
When a substance is nominated for use in compounding, the FDA sorts it into categories while it reviews the evidence. Category 2 holds substances the agency believes may present significant safety risks. BPC-157, TB-500 (a fragment of thymosin beta-4) and injectable GHK-Cu were all in Category 2 until their nominators withdrew the nominations.
The FDA’s Category 2 page, updated April 22, 2026, now lists them under “nominated but withdrawn.” It keeps the agency’s original concerns on the record. For BPC-157, the FDA noted possible immune reactions, challenges in characterizing the peptide and its impurities, and no or only limited safety information for the proposed routes. For TB-500, it said it had not identified any human exposure data. For injectable GHK-Cu, it cited limited human data.
Those concerns are worth translating. Immunogenicity means the body may treat an injected peptide as foreign and mount an immune reaction to it. Impurities are the near-miss molecules created during peptide manufacturing, which can be hard to measure and may behave differently from the intended peptide. Neither concern disappears when a nomination is withdrawn; they are questions the 503A review is meant to weigh.
Several other peptides moved to the same withdrawn list, including CJC-1295, AOD-9604, thymosin alpha-1 and selank. Withdrawal of a nomination is not an approval, and those substances are not on our menu. Our answer on whether CJC-1295 and ipamorelin are legal explains why.
What leaving Category 2 does not do
Leaving the safety-concern list does not, by itself, make a substance eligible for compounding. A 503A pharmacy can only compound from bulk substances that meet specific legal criteria, and for peptides like these that means a place on the FDA’s 503A bulks list. Being removed from one list is not the same as being added to the other.
The FDA describes the legal framework for compounding under sections 503A and 503B of the Food, Drug, and Cosmetic Act, and notes that its Pharmacy Compounding Advisory Committee advises the agency as it builds those bulks lists. Our explainer on 503A and 503B pharmacies covers the difference between the two pharmacy types.
July 2026: the advisory committee vote
The FDA’s Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026. On the first day it considered four peptide substances for the 503A bulks list: BPC-157, TB-500, KPV and MOTs-C.
For BPC-157 and TB-500, the committee voted 8 to 6 to recommend adding them, against the advice of FDA staff. A split vote like that signals contested evidence, especially set against the FDA’s own notes about limited human data and quality concerns.
Advisory committee votes are not binding. The FDA can accept or reject the recommendation, and adding a substance to the 503A bulks list goes through rulemaking, with a proposed rule, a public comment period and a final rule. There is no published timeline for that process.
What is still unsettled, and what to do meanwhile
Until a final rule appears, the honest answer to “can I get BPC-157 or TB-500 from a pharmacy?” is that availability is unsettled. GHK-Cu is due for its own review by early 2027. Anyone who tells you these peptides are fully approved is ahead of the facts.
In the meantime, two points hold regardless of the rule:
- Research-labeled peptides are not a workaround. Products sold “for research use only” skip pharmacy standards for purity, sterility and dose. Our article on research-use-only peptides explains the difference.
- Tested athletes should stay away. BPC-157 and TB-500 are on the WADA prohibited list; see our answer on peptides banned for tested athletes.
The Wolverine stack, which combines BPC-157 and TB-500, depends on both peptides clearing the same process, so its status is tied to the final rule as well.
Other peptides are on firmer ground. Tesamorelin is FDA-approved as Egrifta, sermorelin is compounded, and NAD+ is widely available. Our peptide therapy myths article sorts out what each one can and cannot do.
How Ultimate Male handles peptide questions now
Our peptide therapy program starts with labs and a one-on-one consultation, and we give straight answers about the FDA status of every peptide we discuss. If you are asking about BPC-157 or TB-500, we will tell you where supply stands on the day you call, and what we can offer instead if the answer is not yet.
If you have already used BPC-157 or TB-500 bought online, say so at the consultation. That history helps your provider decide which labs to run, which for peptide patients typically include IGF-1, metabolic and hormone markers.
Ask on the free 10-minute call before you plan around any of these peptides. A consultation is an evaluation, and the status could change again before the final rule.
